Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 68 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2014', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Interstitial Cystitis (Painful Bladder Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interstitial Cystitis (Painful Bladder Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 9
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 12
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 15
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 16
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 17
Afferent Pharmaceuticals, Inc. 17
Allergan, Inc. 18
Aquinox Pharmaceuticals Inc. 19
Astellas Pharma Inc. 20
Kytogenics Pharmaceuticals, Inc. 21
Lipella Pharmaceuticals, Inc. 22
Qu Biologics Inc. 23
Urigen Pharmaceuticals, Inc. 24
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AF-219 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AQX-1125 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ASP-3652 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GM-0111 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GM-1111 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lidocaine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LP-08 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
mesalamine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NEO-5024 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
NEO-5937 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
onabotulinumtoxin A liposomal - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
QBECP - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
URG-101 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates 55
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 60
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 61
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 62
Featured News & Press Releases 62
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 62
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 62
Jul 23, 2013: Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 63
Apr 02, 2013: Taris Doses First Patient In Second Phase II Clinical Study Of LiRIS For Treatment Of Interstitial Cystitis 64
Nov 30, 2011: TARIS Initiates Phase II Clinical Study With LiRIS In Interstitial Cystitis Patients 65
Jun 30, 2011: Urigen Provides Development Update For URG101 65
Mar 09, 2011: TARIS Initiates Clinical Study In Interstitial Cystitis Patients 65
Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101 66
Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis 66
Apr 23, 2010: Urigen Files Request For FDA Meeting 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

List of Tables
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2014 8
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2014 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan, Inc., H2 2014 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2014 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H2 2014 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2014 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2014 22
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H2 2014 23
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H2 2014 55
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2014 60
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2014 61